A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies

Trial Profile

A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs BLU 285 (Primary)
  • Indications Systemic mastocytosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 01 Nov 2017 According to a Blueprint Medicines media release, updated results from this trial are expected in the fourth quarter of 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 09 Mar 2017 According to a Blueprint Medicines Corporation media release, enrollment in the dose escalation portion of this clinical trial is ongoing and company anticipates providing updated data from this clinical trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top